trending Market Intelligence /marketintelligence/en/news-insights/trending/OCITmhKTNq7ltxOe1PYwpg2 content esgSubNav
In This List

Amryt Pharma skin disease drug gets US FDA fast-track status

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Amryt Pharma skin disease drug gets US FDA fast-track status

Amryt Pharma PLC said the U.S. Food and Drug Administration granted fast-track status to its investigational skin disease drug AP101.

SNL Image

The company is developing AP101 as a potential treatment of epidermolysis bullosa, a group of diseases in which the skin gets easily injured, leading to painful blisters. There is currently no FDA-approved treatment for it.

London-based Amryt Pharma is a biopharmaceutical company engaged in developing new therapies for rare and orphan diseases.